Celonic and CureVac Announce Agreement to Manufacture over 100 Million Doses of CureVac’s COVID-19 Vaccine Candidate, CVnCoV

Celonic

Clinical Trials

CureVac Reports Positive Interim Phase 1 Data for its COVID-19 Vaccine Candidate, CVnCoV

CureVac AG

COVID-19

CureVac Expected to Receive up to 252 million Euros from the German Federal Ministry of Research for Further COVID-19 Vaccine Development

CureVac AG

Vaccine Production

Tesla to Make Molecule Printers for German COVID-19 Vaccine Developer CureVac

CureVac AG

Leadership

Company Founder Ingmar Hoerr Succeeds Daniel Menichella as CEO of CureVac AG

CureVac AG